Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P230040/S031

Cordelia Pulmonary Artery Pressure Sensor System (CorPASS)

Endotronix, Inc. · Decision date Oct 16, 2026

MEDTECHLEDGER EXPLANATIONP230040/S031

What did the FDA approve?

The FDA recorded an approval decision on 2026-10-16 for supplement P230040/S031, submitted by Endotronix, Inc. for the Cordelia™ Pulmonary Artery Pressure Sensor System (CorPASS). The supplement is classified as a Real-Time Process submission with the reason Labeling Change - Indications/instructions/shelf life/tradename. The device falls under the implantable hemodynamic system category, cardiovascular specialty, product code MOM.

The recorded scope is limited to revisions to the Instructions for Use concerning recommendations for guidewire selections. This action amends labeling within the existing P230040 application rather than constituting a new approval of the whole system. The source record does not include the revised IFU text, the specific guidewire recommendations, or the original approval date, so the content of the change and any clinical implications remain unknown from this data alone.

FDA approval order statement

revisions to the Instructions for Use (IFU) for the Cordelia Pulmonary Artery regarding recommendations for guidewire selections
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Cardiovascular
Decision date
Oct 16, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P230040/S031
Regulatory pathway
PMA supplement
Product code
MOM
Decision code
APPR
Decision date
Oct 16, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: System, hemodynamic, implantable.

Product code
MOM
FDA device class
3

For the original device and its historical approval scope, see PMA P230040. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P230040 · Original PMA

    Cordella Pulmonary Artery Sensor System (CorPASS)

  2. P230040/S031 received

    Application receipt date recorded by FDA.

  3. P230040/S033 · Related supplement

    Cordella Pulmonary Artery Sensor System (CorPASS)

  4. P230040/S034 · Related supplement

    Cordella Pulmonary Artery Sensor System (CorPASS)

  5. P230040/S031 · FDA decision

    Real-Time Process

  6. P230040/S035 · Related supplement

    Cordella Pulmonary Artery Sensor System (CorPASS)

  7. P230040/S030 · Related supplement

    Cordella Pulmonary Artery Sensor System

Timeline entries are records held by MedtechLedger for P230040. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P230040

Product / regulatory recordCompanyPathwayDecision dateSource
Endotronix, Inc.PMA approvalJun 20, 2024FDA
Endotronix, Inc.PMA supplementSep 25, 2026FDA
Endotronix, Inc.PMA supplementOct 14, 2026FDA
Endotronix, Inc.PMA supplementOct 20, 2026FDA
Endotronix, Inc.PMA supplementOct 29, 2026FDA

Explore the linked device profile

Other records with product code MOM

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Endotronix, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
1415 W. Diehl Rd., Suite 500w, Naperville, IL, 60563

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records